TY - JOUR T1 - Simple Scoring Tool to Estimate Risk of Hospitalization and Mortality in Ambulatory and Emergency Department Patients with COVID-19 JF - medRxiv DO - 10.1101/2021.02.22.21252171 SP - 2021.02.22.21252171 AU - Brandon J. Webb AU - Nicholas M. Levin AU - Nancy Grisel AU - Samuel M. Brown AU - Ithan D. Peltan AU - Emily S. Spivak AU - Mark Shah AU - Eddie Stenehjem AU - Joseph Bledsoe Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252171.abstract N2 - Background Accurate methods of identifying patients with COVID-19 who are at high risk of poor outcomes has become especially important with the advent of limited-availability therapies such as monoclonal antibodies. Here we describe development and validation of a simple but accurate scoring tool to classify risk of hospitalization and mortality.Methods All consecutive patients testing positive for SARS-CoV-2 from March 25-October 1, 2020 within the Intermountain Healthcare system were included. The cohort was randomly divided into 70% derivation and 30% validation cohorts. A multivariable logistic regression model was fitted for 14-day hospitalization. The optimal model was then adapted to a simple, probabilistic score and applied to the validation cohort and evaluated for prediction of hospitalization and 28-day mortality.Results 22,816 patients were included; mean age was 40 years, 50.1% were female and 44% identified as non-white race or Hispanic/Latinx ethnicity. 6.2% required hospitalization and 0.4% died. Criteria in the simple model included: age (0.5 points per decade); high-risk comorbidities (2 points each): diabetes mellitus, severe immunocompromised status and obesity (body mass index≥30); non-white race/Hispanic or Latinx ethnicity (2 points), and 1 point each for: male sex, dyspnea, hypertension, coronary artery disease, cardiac arrythmia, congestive heart failure, chronic kidney disease, chronic pulmonary disease, chronic liver disease, cerebrovascular disease, and chronic neurologic disease. In the derivation cohort (n=16,030) area under the receiver-operator characteristic curve (AUROC) was 0.82 (95% CI 0.81-0.84) for hospitalization and 0.91 (0.83-0.94) for 28-day mortality; in the validation cohort (n=6,786) AUROC for hospitalization was 0.8 (CI 0.78-0.82) and for mortality 0.8 (CI 0.69-0.9).Conclusion A prediction score based on widely available patient attributes accurately risk stratifies patients with COVID-19 at the time of testing. Applications include patient selection for therapies targeted at preventing disease progression in non-hospitalized patients, including monoclonal antibodies. External validation in independent healthcare environments is needed.Competing Interest StatementConflicts of Interest: IP reports salary support through a grant from the National Institutes of Health (U.S.A). SB reports salary support from the U.S. NIH, Centers for Disease Control and the Department of Defense; he also reports receiving support for chairing a data and safety monitoring board for a respiratory failure trial sponsored by Hamilton, effort paid to Intermountain for steering committee work for Faron Pharmaceuticals and Sedana Pharmaceuticals for ARDS work, support from Janssen for Influenza research, and royalties for books on religion and ethics from Oxford University Press/Brigham Young University. BW reports partial salary support from a U.S. Federal grant from AHRQ. ES receives partial salary support through grants from the Centers for Disease Control. At the time of submission, Intermountain Healthcare and the University of Utah have participated in COVID-19 trials sponsored by: Abbvie, Genentech, Gilead, Regeneron, Roche, and the U.S. National Institutes of Health ACTIV and PETAL clinical trials networks; several authors (BW, IP, JB, SB, ES) were site investigators on these trials but received no direct or indirect remuneration for their effort. ES, BJW, SMB and MS are members of the Utah crisis standards of care scarce medication committee. Funding StatementIP reports salary support through a grant from the National Institutes of Health (U.S.A). SB reports salary support from the U.S. NIH, Centers for Disease Control and the Department of Defense; he also reports receiving support for chairing a data and safety monitoring board for a respiratory failure trial sponsored by Hamilton, effort paid to Intermountain for steering committee work for Faron Pharmaceuticals and Sedana Pharmaceuticals for ARDS work, support from Janssen for Influenza research, and royalties for books on religion and ethics from Oxford University Press/Brigham Young University. BW reports partial salary support from a U.S. Federal grant from AHRQ. ES receives partial salary support through grants from the Centers for Disease Control. At the time of submission, Intermountain Healthcare and the University of Utah have participated in COVID-19 trials sponsored by: Abbvie, Genentech, Gilead, Regeneron, Roche, and the U.S. National Institutes of Health ACTIV and PETAL clinical trials networks; several authors (BW, IP, JB, SB, ES) were site investigators on these trials but received no direct or indirect remuneration for their effort. ES, BJW, SMB and MS are members of the Utah crisis standards of care scarce medication committee. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This analysis was approved by the Institutional Review Board at Intermountain Healthcare under #1051342.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn order to protect patient privacy and comply with institutional data use policy, data used in this study are unavailable to upload to public servers. As required by the Intermountain Healthcare Institutional Review Board, data sharing agreement requests to access deidentified versions of the datasets generated and/or analyzed during the current study may be addressed to the Intermountain Office of Research (officeofresearch{at}imail.org) ER -